|
Medical News -
Huntingtons Disease
|
|
Amarin Corporation plc (NASDAQ:AMRN) announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for AMR101 (ultra-pure ethyl-EPA) in patients with Huntington's disease. Thomas Lynch, Chairman and Chief Executive Officer of Amarin, commented "We are pleased to have our EMEA filing for AMR101 in Huntington's disease accepted for review as it is a disorder of great unmet medical need. Read more:
|
